ArticleJournal of cardiovascular development and disease2022
Renin Angiotensin System Blockers and Risk of Mortality in Hypertensive Patients Hospitalized for COVID-19: An Italian Registry.
Article in Journal of cardiovascular development and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- Complications of SARS-CoV-2 Infection During Cardiac Rehabilitation: A Case Series.Cardiology and therapy · 2023Article
- New Perspectives and Strategies for the Management of Hypertension.Journal of cardiovascular development and disease · 2023Article
- Comparing clinical outcomes of ARB and ACEi in patients hospitalized for acute COVID-19.Scientific reports · 2023Article
- Role of Angiotensin II in Cardiovascular Diseases: Introducing Bisartans as a Novel Therapy for Coronavirus 2019.Biomolecules · 2023Review
- The spike effect of acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 vaccines on blood pressure.European journal of internal medicine · 2023Review
- mRNA Metabolism and Hypertension.Biomedicines · 2023Review
- Rethinking the Role of the Renin-Angiotensin System in the Pandemic Era of SARS-CoV-2.Journal of cardiovascular development and disease · 2023Article
- Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options.Life (Basel, Switzerland) · 2022Review
- The effects of antihypertensive medications on severity and outcomes of COVID19.Journal of human hypertension · 2022Article
- COVID-19, vaccines and deficiency of ACEEuropean journal of internal medicine · 2022Review
- Article
- Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis.Journal of cardiovascular development and disease · 2022Review
- Endothelial Dysfunction in COVID-19: A Unifying Mechanism and a Potential Therapeutic Target.Biomedicines · 2022Review
- Relation Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Severity.Cureus · 2022Article
- Charlson comorbidity index, neutrophil-to-lymphocyte ratio and undertreatment with renin-angiotensin-aldosterone system inhibitors predict in-hospital mortality of hospitalized COVID-19 patients during the omicron dominant period.Frontiers in immunology · 2022Article
- Impact of hypertension on long-term humoral and cellular response to SARS-CoV-2 infection.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is uncertain whether exposure to renin-angiotensin system (RAS) modifiers affects the severity of the new coronavirus disease 2019 (COVID-19) because most of the available studies are retrospective.
methodsWe tested the prognostic value of exposure to RAS modifiers (either angiotensin-converting enzyme inhibitors [ACE-Is] or angiotensin receptor blockers [ARBs]) in a prospective study of hypertensive patients with COVID-19. We analyzed data from 566 patients (mean age 75 years, 54% males, 162 ACE-Is users, and 147 ARBs users) hospitalized in five Italian hospitals. The study used systematic prospective data collection according to a pre-specified protocol. All-cause mortality during hospitalization was the primary outcome.
resultsSixty-six patients died during hospitalization. Exposure to RAS modifiers was associated with a significant reduction in the risk of in-hospital mortality when compared to other BP-lowering strategies (odds ratio [OR]: 0.54, 95% confidence interval [CI]: 0.32 to 0.90,
conclusionsThis prospective study indicates that exposure to ARBs reduces mortality in hospitalized patients with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.